{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,3]],"date-time":"2026-07-03T15:48:25Z","timestamp":1783093705439,"version":"3.54.6"},"reference-count":46,"publisher":"American Society of Hematology","issue":"15","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,8,12]]},"abstract":"<jats:sec>\n                  <jats:title>Abstract<\/jats:title>\n                  <jats:p>In patients with chronic lymphocytic leukemia (CLL)\/small lymphocytic lymphoma (SLL), high-risk cytogenetic features such as del(17p), del(11q), and unmutated immunoglobulin variable heavy chain (IGHV) may be associated with unfavorable outcomes. In this large retrospective cohort study, data from a nationwide electronic health record\u2013derived deidentified database were analyzed to assess real-world overall survival (rwOS) among patients treated with first-line (1L) ibrutinib with and without high-risk cytogenetic features (ie, del(17p), del(11q), unmutated IGHV). Inverse probability of treatment weighting was used to account for differences in patient characteristics between cohorts. Of 1242 patients included, 969 and 273 had high- and non\u2013high-risk CLL\/SLL, with a mean age of 70.0 and 70.8 years, and a median follow-up of 32 and 31 months, respectively. Within the high-risk cohort, 32.9%, 36.7%, and 58.7% had the presence of del(17p), del(11q), and unmutated IGHV, respectively. The median rwOS was not reached for either cohort; the hazard ratio (HR) comparing rwOS between the 2 cohorts was 1.09 (95% confidence interval [CI], 0.79-1.51). In a sensitivity analysis in which del(11q) was not part of the high-risk definition, similar results were found, with a HR of 1.19 (95% CI, 0.86-1.64) and median rwOS not reached for either cohort. Similarly, among the subgroup of patients with Medicare coverage, the HR was 0.98 (95% CI, 0.63-1.53), and median rwOS was not reached. In this real-world study using a large community health care data set, there was no difference in rwOS between patients treated with 1L ibrutinib with and without high-risk cytogenetic features.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1182\/bloodadvances.2024015417","type":"journal-article","created":{"date-parts":[[2025,5,12]],"date-time":"2025-05-12T10:44:05Z","timestamp":1747046645000},"page":"3801-3809","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":3,"title":["Real-world survival outcomes in first-line ibrutinib-treated patients with high-risk CLL\/SLL"],"prefix":"10.1182","volume":"9","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2088-0899","authenticated-orcid":false,"given":"John N.","family":"Allan","sequence":"first","affiliation":[{"name":"1Division of Hematology and Medical Oncology, Weill Cornell Medicine, New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7873-0685","authenticated-orcid":false,"given":"Tao","family":"Ran","sequence":"additional","affiliation":[{"name":"2Janssen Scientific Affairs, LLC, a Johnson & Johnson Company, Titusville, NJ"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhijie","family":"Ding","sequence":"additional","affiliation":[{"name":"3Janssen Scientific Affairs, LLC, a Johnson & Johnson Company, Horsham, PA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinghua","family":"He","sequence":"additional","affiliation":[{"name":"2Janssen Scientific Affairs, LLC, a Johnson & Johnson Company, Titusville, NJ"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alex","family":"Bokun","sequence":"additional","affiliation":[{"name":"3Janssen Scientific Affairs, LLC, a Johnson & Johnson Company, Horsham, PA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9605-3980","authenticated-orcid":false,"given":"Zaina P.","family":"Qureshi","sequence":"additional","affiliation":[{"name":"3Janssen Scientific Affairs, LLC, a Johnson & Johnson Company, Horsham, PA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2481-7504","authenticated-orcid":false,"given":"Susan M.","family":"O\u2019Brien","sequence":"additional","affiliation":[{"name":"4Division of Hematology and Oncology, Department of Medicine, University of California Irvine, Orange, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2025,7,25]]},"reference":[{"issue":"5","key":"2025081209313510700_bib1","first-page":"409","article-title":"Cancer treatment and survivorship statistics, 2022","volume":"72","author":"Miller","year":"2022","journal-title":"CA Cancer J Clin"},{"key":"2025081209313510700_bib2","unstructured":"National Cancer Institute\n          . SEER cancer statistics review (CSR), 1975-2018. Accessed 7 June 2024. https:\/\/seer.cancer.gov\/archive\/csr\/1975_2018\/index.html."},{"key":"2025081209313510700_bib3","unstructured":"National Cancer Institute\n          . Cancer stat facts: leukemia \u2014 chronic lymphocytic leukemia (CLL). Accessed 7 June 2024. https:\/\/seer.cancer.gov\/statfacts\/html\/clyl.html."},{"key":"2025081209313510700_bib4","doi-asserted-by":"crossref","first-page":"788761","DOI":"10.3389\/fonc.2021.788761","article-title":"Biology and treatment of high-risk CLL: significance of complex karyotype","volume":"11","author":"Chatzikonstantinou","year":"2021","journal-title":"Front Oncol"},{"issue":"11","key":"2025081209313510700_bib5","doi-asserted-by":"crossref","first-page":"1361","DOI":"10.1002\/ajh.25956","article-title":"The complex karyotype and chronic lymphocytic leukemia: prognostic value and diagnostic recommendations","volume":"95","author":"Jondreville","year":"2020","journal-title":"Am J Hematol"},{"issue":"11","key":"2025081209313510700_bib6","doi-asserted-by":"crossref","first-page":"1205","DOI":"10.1182\/blood-2018-09-873083","article-title":"Cytogenetic complexity in chronic lymphocytic leukemia: definitions, associations, and clinical impact","volume":"133","author":"Baliakas","year":"2019","journal-title":"Blood"},{"issue":"4","key":"2025081209313510700_bib7","doi-asserted-by":"crossref","first-page":"868","DOI":"10.3324\/haematol.2021.278304","article-title":"The complex karyotype landscape in chronic lymphocytic leukemia allows the refinement of the risk of Richter syndrome transformation","volume":"107","author":"Visentin","year":"2022","journal-title":"Haematologica"},{"issue":"12","key":"2025081209313510700_bib8","doi-asserted-by":"crossref","first-page":"1956","DOI":"10.3324\/haematol.2018.187583","article-title":"TP53 aberrations in chronic lymphocytic leukemia: an overview of the clinical implications of improved diagnostics","volume":"103","author":"Campo","year":"2018","journal-title":"Haematologica"},{"issue":"5","key":"2025081209313510700_bib9","doi-asserted-by":"crossref","first-page":"1504","DOI":"10.3390\/cancers15051504","article-title":"Next generation BTK inhibitors in CLL: evolving challenges and new opportunities","volume":"15","author":"Frustaci","year":"2023","journal-title":"Cancers (Basel)"},{"issue":"5","key":"2025081209313510700_bib10","doi-asserted-by":"crossref","first-page":"1583","DOI":"10.3390\/cancers15051583","article-title":"Emerging therapies in CLL in the era of precision medicine","volume":"15","author":"Iyer","year":"2023","journal-title":"Cancers (Basel)"},{"key":"2025081209313510700_bib11","unstructured":"IMBRUVICA\u00ae (ibrutinib) capsules, for oral use; IMBRUVICA (ibrutinib) tablets, for oral use; IMBRUVICA\u00ae (ibrutinib) oral suspension. Pharmacyclics LLC. 2024. Accessed 7 June 2024. https:\/\/www.rxabbvie.com\/pdf\/imbruvica_pi.pdf."},{"key":"2025081209313510700_bib12","unstructured":"CALQUENCE (acalabrutinib) tablets, for oral use. AstraZeneca Pharmaceuticals LP. 2022. Accessed 7 June 2024. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2022\/216387Orig2s000Correctedlbl.pdf."},{"key":"2025081209313510700_bib13","unstructured":"BRUKINSA (zanubrutinib) capsules, for oral use. BeiGene. 2024. Accessed 7 June 2024. https:\/\/d1e94vsyskgtht.cloudfront.net\/brukinsa\/pdfs\/brukinsa-prescribing-information.pdf."},{"issue":"18","key":"2025081209313510700_bib14","doi-asserted-by":"crossref","first-page":"3974","DOI":"10.1158\/1078-0432.CCR-24-0919","article-title":"Improving collection and analysis of overall survival data","volume":"30","author":"Rodriguez","year":"2024","journal-title":"Clin Cancer Res"},{"key":"2025081209313510700_bib15","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1016\/j.ejca.2020.06.015","article-title":"Progression-free survival is a suboptimal predictor for overall survival among metastatic solid tumour clinical trials","volume":"136","author":"Pasalic","year":"2020","journal-title":"Eur J Cancer"},{"issue":"17","key":"2025081209313510700_bib16","doi-asserted-by":"crossref","first-page":"2874","DOI":"10.1200\/JCO.2008.20.4107","article-title":"Issues in using progression-free survival when evaluating oncology products","volume":"27","author":"Fleming","year":"2009","journal-title":"J Clin Oncol"},{"issue":"5","key":"2025081209313510700_bib17","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1056\/NEJMoa1817073","article-title":"Ibrutinib-rituximab or chemoimmunotherapy for chronic lymphocytic leukemia","volume":"381","author":"Shanafelt","year":"2019","journal-title":"N Engl J Med"},{"issue":"11","key":"2025081209313510700_bib18","doi-asserted-by":"crossref","first-page":"3440","DOI":"10.1182\/bloodadvances.2021006434","article-title":"Up to 8-year follow-up from RESONATE-2: first-line ibrutinib treatment for patients with chronic lymphocytic leukemia","volume":"6","author":"Barr","year":"2022","journal-title":"Blood Adv"},{"issue":"3","key":"2025081209313510700_bib19","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1038\/s41375-019-0602-x","article-title":"Long-term efficacy and safety of first-line ibrutinib treatment for patients with CLL\/SLL: 5 years of follow-up from the phase 3 RESONATE-2 study","volume":"34","author":"Burger","year":"2020","journal-title":"Leukemia"},{"issue":"1","key":"2025081209313510700_bib20","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1007\/s40801-022-00332-4","article-title":"Systematic literature review of real-world effectiveness results data for first-line ibrutinib in chronic lymphocytic leukemia and small lymphocytic lymphoma","volume":"10","author":"Lee","year":"2023","journal-title":"Drugs Real World Outcomes"},{"issue":"17","key":"2025081209313510700_bib21","doi-asserted-by":"crossref","first-page":"1910","DOI":"10.1182\/blood-2017-10-810044","article-title":"Single-agent ibrutinib in treatment-naive and relapsed\/refractory chronic lymphocytic leukemia: a 5-year experience","volume":"131","author":"O\u2019Brien","year":"2018","journal-title":"Blood"},{"key":"2025081209313510700_bib22","doi-asserted-by":"crossref","first-page":"S179","DOI":"10.1016\/S2152-2650(24)00565-2","article-title":"Final analysis of the RESONATE-2 study: up to 10 years of follow-up of first-line ibrutinib treatment in patients with chronic lymphocytic leukemia\/small lymphocytic lymphoma","volume":"24","author":"Burger","year":"2024","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"5","key":"2025081209313510700_bib23","doi-asserted-by":"crossref","first-page":"e74","DOI":"10.1002\/hem3.74","article-title":"First-line ibrutinib treatment in patients with chronic lymphocytic leukemia is associated with overall survival rates similar to those of an age-matched general population: a pooled post hoc analysis","volume":"8","author":"Ghia","year":"2024","journal-title":"Hemasphere"},{"issue":"6","key":"2025081209313510700_bib24","doi-asserted-by":"crossref","first-page":"1375","DOI":"10.1080\/10428194.2021.2020779","article-title":"Up to 6.5 years (median 4 years) of follow-up of first-line ibrutinib in patients with chronic lymphocytic leukemia\/small lymphocytic lymphoma and high-risk genomic features: integrated analysis of two phase 3 studies","volume":"63","author":"Burger","year":"2022","journal-title":"Leuk Lymphoma"},{"issue":"5","key":"2025081209313510700_bib25","doi-asserted-by":"crossref","first-page":"1050","DOI":"10.1093\/annonc\/mdx031","article-title":"Optimal sequencing of ibrutinib, idelalisib, and venetoclax in chronic lymphocytic leukemia: results from a multicenter study of 683 patients","volume":"28","author":"Mato","year":"2017","journal-title":"Ann Oncol"},{"key":"2025081209313510700_bib26","doi-asserted-by":"crossref","first-page":"1109950","DOI":"10.3389\/fonc.2022.1109950","article-title":"Editorial: Biology and treatment of high-risk CLL","volume":"12","author":"Tausch","year":"2022","journal-title":"Front Oncol"},{"key":"2025081209313510700_bib27","doi-asserted-by":"crossref","first-page":"E61","DOI":"10.5888\/pcd10.120137","article-title":"Prevalence of multiple chronic conditions among Medicare beneficiaries, United States, 2010","volume":"10","author":"Lochner","year":"2013","journal-title":"Prev Chronic Dis"},{"issue":"10","key":"2025081209313510700_bib28","doi-asserted-by":"crossref","first-page":"1796","DOI":"10.3324\/haematol.2017.171041","article-title":"Characterization of atrial fibrillation adverse events reported in ibrutinib randomized controlled registration trials","volume":"102","author":"Brown","year":"2017","journal-title":"Haematologica"},{"key":"2025081209313510700_bib29","doi-asserted-by":"publisher","DOI":"10.48550\/arXiv.2001.09765","article-title":"Model-assisted cohort selection with bias analysis for generating large-scale cohorts from the EHR for oncology research","author":"Birnbaum","year":"13  2020","journal-title":"arXiv"},{"key":"2025081209313510700_bib30","doi-asserted-by":"publisher","DOI":"10.1101\/2020.03.16.20037143","article-title":"Comparison of population characteristics in real-world clinical oncology databases in the US: Flatiron Health, SEER, and NPCR","author":"Ma","year":"7  2020","journal-title":"medRxiv"},{"issue":"6","key":"2025081209313510700_bib31","doi-asserted-by":"crossref","first-page":"1281","DOI":"10.1111\/1475-6773.13669","article-title":"Validation analysis of a composite real-world mortality endpoint for patients with cancer in the United States","volume":"56","author":"Zhang","year":"2021","journal-title":"Health Serv Res"},{"issue":"1","key":"2025081209313510700_bib32","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/S1470-2045(18)30788-5","article-title":"Ibrutinib plus obinutuzumab versus chlorambucil plus obinutuzumab in first-line treatment of chronic lymphocytic leukaemia (iLLUMINATE): a multicentre, randomised, open-label, phase 3 trial","volume":"20","author":"Moreno","year":"2019","journal-title":"Lancet Oncol"},{"issue":"26","key":"2025081209313510700_bib33","doi-asserted-by":"crossref","first-page":"2517","DOI":"10.1056\/NEJMoa1812836","article-title":"Ibrutinib regimens versus chemoimmunotherapy in older patients with untreated CLL","volume":"379","author":"Woyach","year":"2018","journal-title":"N Engl J Med"},{"issue":"suppl 1","key":"2025081209313510700_bib34","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1182\/blood-2020-134437","article-title":"2220: Outcomes of first-line ibrutinib in patients with chronic lymphocytic leukemia\/small lymphocytic lymphoma (CLL\/SLL) and high-risk genomic features with up to 6.5 years follow-up: integrated analysis of two phase 3 studies (RESONATE-2 and iLLUMINATE)","volume":"136","author":"Burger","year":"2020","journal-title":"Blood"},{"issue":"12","key":"2025081209313510700_bib35","doi-asserted-by":"crossref","first-page":"2749","DOI":"10.1007\/s00277-019-03830-8","article-title":"Single-agent ibrutinib in RESONATE-2 and RESONATE versus treatments in the real-world PHEDRA databases for patients with chronic lymphocytic leukemia","volume":"98","author":"Salles","year":"2019","journal-title":"Ann Hematol"},{"issue":"14","key":"2025081209313510700_bib36","doi-asserted-by":"crossref","first-page":"2593","DOI":"10.1158\/1078-0432.CCR-22-2779","article-title":"Outcomes in patients with high-risk features after fixed-duration ibrutinib plus venetoclax: phase II CAPTIVATE study in first-line chronic lymphocytic leukemia","volume":"29","author":"Allan","year":"2023","journal-title":"Clin Cancer Res"},{"issue":"7","key":"2025081209313510700_bib37","doi-asserted-by":"crossref","first-page":"3292","DOI":"10.1007\/s12325-021-01991-5","article-title":"Real-world clinical outcomes of first-line ibrutinib or chemoimmunotherapy in patients with chronic lymphocytic leukemia by risk status","volume":"39","author":"Huang","year":"2022","journal-title":"Adv Ther"},{"issue":"2","key":"2025081209313510700_bib38","doi-asserted-by":"crossref","first-page":"324","DOI":"10.3390\/medicina59020324","article-title":"Real-world clinical outcomes and adverse events in patients with chronic lymphocytic leukemia treated with ibrutinib: a single-center retrospective study","volume":"59","author":"Moldovianu","year":"2023","journal-title":"Medicina (Kaunas)"},{"issue":"26","key":"2025081209313510700_bib39","doi-asserted-by":"crossref","first-page":"1910","DOI":"10.1056\/NEJM200012283432602","article-title":"Genomic aberrations and survival in chronic lymphocytic leukemia","volume":"343","author":"D\u00f6hner","year":"2000","journal-title":"N Engl J Med"},{"issue":"11","key":"2025081209313510700_bib40","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1016\/j.clml.2019.07.004","article-title":"Long-term studies assessing outcomes of ibrutinib therapy in patients with del(11q) chronic lymphocytic leukemia","volume":"19","author":"Kipps","year":"2019","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"21","key":"2025081209313510700_bib41","doi-asserted-by":"crossref","first-page":"5104","DOI":"10.3390\/jcm10215104","article-title":"Treatment options for elderly\/unfit patients with chronic lymphocytic leukemia in the era of targeted drugs: a comprehensive review","volume":"10","author":"Fresa","year":"2021","journal-title":"J Clin Med"},{"issue":"8","key":"2025081209313510700_bib42","doi-asserted-by":"crossref","first-page":"2690","DOI":"10.1002\/cam4.3855","article-title":"Overall survival, adverse events, and economic burden in patients with chronic lymphocytic leukemia receiving systemic therapy: real-world evidence from the medicare population","volume":"10","author":"Goyal","year":"2021","journal-title":"Cancer Med"},{"issue":"2","key":"2025081209313510700_bib43","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1093\/annonc\/mdw547","article-title":"Management of chronic lymphocytic leukemia (CLL) in the elderly: a position paper from an international Society of Geriatric Oncology (SIOG) Task Force","volume":"28","author":"Stauder","year":"2017","journal-title":"Ann Oncol"},{"issue":"20","key":"2025081209313510700_bib44","doi-asserted-by":"crossref","first-page":"2142","DOI":"10.1182\/blood.2022016953","article-title":"Ventricular arrhythmias and sudden death events following acalabrutinib initiation","volume":"140","author":"Bhat","year":"2022","journal-title":"Blood"},{"issue":"7","key":"2025081209313510700_bib45","doi-asserted-by":"crossref","first-page":"1554","DOI":"10.1038\/s41375-023-01869-1","article-title":"Evaluation of bleeding events in patients receiving acalabrutinib therapy","volume":"37","author":"Kumar","year":"2023","journal-title":"Leukemia"},{"issue":"20","key":"2025081209313510700_bib46","doi-asserted-by":"crossref","first-page":"2096","DOI":"10.1182\/blood.2022017791","article-title":"Cardiotoxicity in patients treated with acalabrutinib","volume":"140","author":"Langerbeins","year":"2022","journal-title":"Blood"}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/9\/15\/3801\/2404458\/blooda_adv-2024-015417-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/9\/15\/3801\/2404458\/blooda_adv-2024-015417-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,12]],"date-time":"2025-08-12T13:31:51Z","timestamp":1755005511000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/9\/15\/3801\/537228\/Real-world-survival-outcomes-in-first-line"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,25]]},"references-count":46,"journal-issue":{"issue":"15","published-print":{"date-parts":[[2025,8,12]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2024015417","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,8,12]]},"published":{"date-parts":[[2025,7,25]]}}}